Stephen P. Ethier and a panel of leading investigators comprehensively analyze the cellular, molecular, and endocrine factors in the development of cancers of the breast, prostate, endometrium, and ovary. Concentrating on defining the most important unresolved issues in the field, the authors review how steroid hormones function to regulate normal mammary gland homeostasis in humans, with particular emphasis on the roles of estrogen, progesterone, and growth factors. Comprehensive and up-to-date, Endocrine Oncology offers both basic and clinical researchers not only the latest molecular and cellular findings on endocrine cancers, but also a powerful critical analysis that will prove invaluable to all endocrinologists and oncologists working in the area today.

Energy Balance and Cancer, Epidemiology and Overview is the first in a series of monographs to address the multiple facets of the world wide pandemic of overweight and obesity and its relation to cancer. This volume, authored by leading experts in their perspective fields, provides a broad and comprehensive overview of the problem from the epidemiologic viewpoint with focus on both general and special populations as well as a description of potential molecular mechanisms and reviews of the latest studies of factors impacting the association of energy balance and cancer including the effects of genetics, caloric restriction, exercise, behavior and the built environment. The collected chapters and the authors contributing to this initial volume represent a transdisciplinary approach to analyze and develop novel approaches to understand and solve what, up to now, is a globally refractory problem. The book is written to be understandable and informative to individuals from all concerned disciplines. It should serve to orient students, investigators, nutritionists, public health officials, community planners, clinicians and policy makers to the extent of the problem, its multiple dimensions and potential approaches for research and corrective interventions.

"Apoptosome" is the first book that presents a concise synthesis of recent developments in the understanding of how the activation of the cell death cascade is handled by a cytosolic signalling platform known as the apoptosome.

The book also discusses how insights into the regulation of apoptosome may be exploited for designing new drugs aimed at interfere with a plethora of pathogenetic processes involved in human diseases.

The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatment of diseases associated with apoptosis.

This book will be a valuable resource for researchers investigating the role of apoptosome-dependent cell death in cancer and other diseases, for researchers investigating the molecular mechanism of chemotherapeutic agents and drug-resistance and for physicians using chemotherapeutic agents. Additionally, this book will be an important educational source for PhD students and MD students specializing in molecular and cell biology, and to anybody interested in science, medicine, as well as in recent developments of the ideas and concepts of the molecular biology of programmed cell death.

This second edition provides an overview of recent developments and approaches used by researchers to investigate the properties and functions of mammary epithelial and stem cells, which will contribute to understand the heterogeneity of the mammary gland and of breast cancer. Chapters detail processes used to characterize stem cells, single cell RNA sequencing, computational methods, sophisticated imaging techniques, and a variety of model systems, among others. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Mammary Stem Cells: Methods and Protocols, Second Edition aims to make available protocols used to navigate the intricate behavior of mammary stem cells and to gain further knowledge to take us closer to the design of innovative strategies to prevent and treat breast cancer.

"Healing With Words: A Writer's Cancer Journey" is a compassionate and wry self-help memoir written by an award-winning prolific author, nurse and poet, who at the age of forty-seven found her life shattered first by a DCIS (early breast cancer) diagnosis and five years later by another, seemingly unrelated and incurable cancer--multiple myeloma. The book includes the author's experiences, reflections, poetry and journal entries, in addition to writing prompts for readers to express their own personal story. Raab's journals have provided a safe haven and platform to validate and express her feelings. Raab views journaling to be like a daily vitamin--in that it heals, detoxifies and is essential for optimal health.
Readers will learn to: Understand the importance of early cancer detection and how to take control of their own health Discover the power of writing to release bottled-up emotions Learn how the process of journaling can facilitate healing See how a cancer diagnosis can be a riveting event which can renew and change a person in a unique way
Praise for Raab's "Healing With Words":
"One woman's story, beautifully told and inspiring to those for whom journaling will ease a cancer diagnosis."
--Barbara Delinsky, author UPLIFT: Secrets from the Sisterhood of Breast Cancer Survivors
"Time after time, Diana articulates incisively the thoughts and feelings that convey hoped-for meaning and encouragement. She is a woman who knows what it is to live fully in the face of mortality. She will add value to the life of every person who reads this book. Healing With Words resonates at a spiritual level for me."
--Sena Jeter Naslund, author of Ahab's Wife and Abundance: A Novel of Marie Antoinette
Author's proceeds from the sale of this book donated to benefit the Mayo Clinic Foundation
Learn more at www.DianaRaab.com
Another inspirational book from Loving Healing Press www.LovingHealing.com
HEA039031 Health & Fitness: Diseases - Breast Cancer
SEL501000 Self-Help: Journal Writing
MED058160 Nursing - Oncology & Cancer

This volume provides an overview on the influence of Extracellular Matrix (ECM) on tumor progression. It covers topics such as signaling induced by structural ECM proteins including collagen and fibronectin, the control of ECM deposition and the turnover in tumors. Also discussed are the migration of cells through basement membranes and the function of proteoglycans including lumican and veriscan in tumor progression. Biomaterial-based in-vitro models as well as C. elegans models of the tumor microenvironment are used to show how these models can lead to a greater understanding of the disease mechanisms that promote cancer progression. The book addresses researchers working on cancer biology or ECM, and oncologists alike.

In Tumor Targeting in Cancer Therapy, Dr. Michel Page and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand.

Colorectal cancer has for more than two decades served as the paradigm for the multi-step concept of cancer initiation and progression. Perhaps more than any other organ site, cancer of the colon is extensively characterized at the molecular level. We are now entering a time when molecular classification, rather than histologic classification, of cancer subtypes is driving the development of clinical trials with emerging targeted therapies. The book will focus on the progression from the identification of mutations that drive colorectal cancer initiation and progression to the search for novel therapies to treat the disease.

Infection with the human immunodeficiency virus (HIV) and human T-cell lymphotropic virus type I (HTLV-I) is known to be associated with an increased risk of neoplastic disorders, especially Kaposi's sarcoma and aggressive B-cell lymphoma for the former, and T-cell lymphoma for the latter. The information obtained from the study of these infections has led to remarkable advances in our understanding of the immune system, as well as the biology of human neoplasms. The management of malignant diseases in such patients also poses substantial challenges to clinicians. This book provides an overview of the epidemiology, biology, clinical features, and clinical management of neoplasms occurring in such individuals. It is an important resource for clinicians treating these diseases, and for basic scientists who have an interest in this field.

Prostaglandins, Leukotrienes, and Cancer is a multi-volume series that will focus on an emerging area of cancer research. In 1968, R.H. Williams first reported that elevated prostaglandin levels are present in human medullary car- cinoma. Since that time, the concept that arachidonic acid metabolites may be in- volved in cancer has expanded to include every aspect of the disease from cell transformation through metastasis. Prostaglandins and leukotrienes are generic terms used to describe a family of bioactive lipids produced from unsaturated fatty acids (principally from arachidonic acid) via the cyclooxygenase and lipoxygenase pathways, respec- tively. Cyclooxygenase products consist of diverse products such as prosta- glandin E2 (POE ), prostacyclin (POI ) and thromboxane A2 (TXA ), whereas 2 2 2 lipoxygenase products consist of hydroperoxy fatty acids and mono-, di- and tri-hydroxy acids including leukotrienes. The precursor fatty acids for the cyclooxygenase and lipoxygenase pathways are present in cellular phospholipids. This finding established an important control point in their biosynthesis-the release of substrate. This occurs in response to numerous stimuli that act at the cell surface. Dr. Bengl Samuelsson's extensive study of the metabolism of pros- taglandins indicated that they are rapidly inactivated on a single pass through pulmonary circulation. Thus, they cannot act as circulating hormones and appear to be made on demand in or in the vicinity of target tissues leading to the concept that prostaglandins are local hormones or autocoids.

This textbook discusses the systemic consequences of cancer, covering a range of topics from tumor-promoting systemic effects to the development of cachexia, as summarized in the introductory chapter 1. Part I of this textbook focuses on tumor-promoting systemic effects and begins with a chapter on how tumor-derived extracellular vesicles and particles lay the foundation for future metastases (Chapter 2). Chapter 3 discusses how metastatic cells that have colonized the bone impact the local bone microenvironment, neighboring muscles, and host physiology. Chapter 4 summarizes the available strategies for targeting metastatic cancer and emphasizes the need to incorporate a systemic view of the disease. Following this overview of the systemic effects of cancer progression, Part II of the textbook discusses cancer-induced cachexia, a debilitating systemic effect of advanced cancer. Chapters 5-7 examine the key signaling pathways (interleukin-6/GP130, NF-kB, and muscle proteolysis) that drive the development of cancer cachexia. Chapters 8 and 9 in Part III of this textbook explore how toxicities from anti-cancer therapy are associated with the onset of cachexia in cancer patients, and provide insight into potential approaches to simultaneously target both cancer and cachexia. Chapters 10 and 11 (Part IV) conclude this textbook by outlining promising approaches for the diagnosis and treatment of cachexia as well as strategies to prevent the development of cachexia through exercise. An understanding of the systemic effects of cancer is essential for the design of effective anti-cancer and anti-cachexia treatment strategies. As such, this textbook provides key information for both students and scientists engaged in cancer research and oncology.

Sphingolipids are lipid components of the plasma membrane of eukaryotic cells with an important function in signaling mechanisms in the cell. This book provides insight into the physiological and pathophysiological role of sphingolipids and in particular its derivative ceramide. The function of Sphingolipids in cell signaling with regard to infectious and lung diseases, cancer, cardiovascular diseases and neuropsychiatric disorders are described and treated in distinct parts. Together with Volume 215 from the same Editors, the collection represents a unique, comprehensive work on Sphingolipids, providing information on both: Sphingolipid basic biology as well as its important function in a (patho)physiological context. The book is written for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians in pharmacology, oncology, cardiology, neurology and infectious disease. "

This book provides the readers with an overview of research on p53, which has been shown to play a role in numerous crucial biological pathways in normal and cancer cells. Leading scientist in the field, who have all made direct contributions to the understanding of the molecular events underpinning p53 function, have been invited to contribute the various chapters, which discuss the current knowledge of the signaling cascades that are activated by mutations in p53 and overexpression of MDM2, frequently found in human cancer and are major causes of oncogenesis.

This book features chapters on the molecular basis of oncogenesis induced by gain of function mutation of p53, signaling pathways induced by MDM2 overexpression, control of mutant or wild-type p53 function by MDM2 and MDMX, p53 mutation in hereditary cancer and structural aspects that activate mutant p53 which can be targeted by drug therapy. This book should be useful for scientists at all levels.

These proceedings emanate from the Second Prouts Neck Conference on prostate cancer held on October 17-19, 1986, the theme of which was treat ment, with focus on current issues and future research that is needed to answer critical questions related to optimal management of the various stages of prostate cancer. The objective was to reveal the most crucial problems impeding progress and to crystallize the combined multidisci plinary input generated by the conference into focused concepts or recommendations for presentation to the National Cancer Institute (NCI), with the ultimate intent of targeting research to address the priority issues identified. In organizing the workshop, every effort was made to maintain a multidisciplinary balance among nationally renowned authorities on prostate cancer. Thus, leading surgeons, radiation and medical onco logists and biostatisticians were in equal presence. While there were spirited exchanges with careful scrutiny and critique of all data pre sented, there was a common belief that the challenge of prostate cancer would be best approached in this multidisciplinary Organ Systems-oriented fashion. During the course of the conference, it became apparent to all present that major nomenclature and procedural barriers have made it generally difficult, and frequently impossible, to compare results of clinical research."

Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is pri- rily addressed to scientists working on recombinant antibodies as well as cli- cians involved with antibody-based therapies. As with other volumes of this series, we placed the main focus on providing detailed protocols describing procedures step-by-step. Moreover, each protocol supplies a troubleshooting guide containing detailed information on possible problems and hints for pot- tial solutions. Antibody technology is a subject of constant and rapid change. This volume, therefore, does not attempt to cover all possible current experimental approaches in the field. Rather, we present carefully selected protocols, written by competent authors who have successfully verified the particular method described. Given our own professional backgrounds and interest in oncology, we chose to conc- trate chiefly on therapeutic agents for cancer patients.

Biochemical Modulation at the present time defines an area of study in which the intracellular metabolism of a given anti cancer agent is modulated (usually by a noncytotoxic agent or a cytotoxic agent at sufficiently low dosage to make it non cytotoxic) in order to either increase the effectiveness of the particular agent against tumor cells or decrease its cytotox icity against normal cells. The major focus of modulation has been the agents 5-fluorouracil (FUra), arabinofuranosylcytosine (ara-C), methotrexate (MTX) and a few alkylating agents. The major thrust of the studies has been to increase the flow of the anticancer agent along the pathway responsible for the formation of the cytotoxic species: for example, FUra to FUTP or ara-C to ara-CTP. While in most cases the application of research re sults to clinical trials does not require the subsequent exper tise of the laboratory researchers, application of biochemical modulatory schemes to clinical protocols necessitate a dramatic break with the past procedures. As shown in the laboratory clinical loop below, close collaboration between the laboratory and clinical investigator is essential. While the laboratory REDEFINE TECHNOLOGY, TESTS OR QUESTIONS FOR FURTHER THERAPEUTIC ADVANCE CLINICAL EXPERIMENTAL PROTOCOL (LABORATORY) RESEARCH STUDIES DEFINE AND TEST APPROPRIATE SCIENTIFIC PARAMETERS results define rationally-based regimens, it is essential that the clinical protocols contain the requirement that clinical material (either tumor or normal tissues) be sampled to deter mine whether the biochemical modulation being proposed is in fact beinq accomplished."

The epigenetic regulation plays an important role in normal development and maintenance of tissue specific genes expression in humans and the disturbance of these patterns lead to changes involved in tumor formation. More recently, epigenetic changes have been observed in early stages of tumor development and together with the genetic alterations have been defined as abnormalities, necessary for cancer initiation and progression. In, Cancer Epigenetics: Methods and Protocols, expert researchers reviewed these epigenetics changes in different tumor types and described several technologies that are currently available to detect epigenetic changes. These technologies have lead to a better understanding of the processes in normal and cancerous cells. Written in the highly successful Methods in Molecular Biology (TM) series format, the chapters include the kind of detailed description and implementation advice that is crucial for getting optimal results in the laboratory. Thorough and intuitive, Cancer Epigenetics: Methods and Protocols aids scientists in continuing to study epigenetic alterations used in clinical practice as biomarkers of early cancerous lesions or markers of progression and prognosis.

This book presents comprehensive coverage on the importance of good nutrition in the treatment and management of obesity, cancer and diabetes. Naturally occurring bioactive compounds are ubiquitous in most dietary plants available to humans and provide opportunities for the management of diseases. The text provides information about the major causes of these diseases and their association with nutrition. The text also covers the role of dietary phytochemicals in drug development and their pathways. Later chapters emphasize novel bioactive compounds as anti-diabetic, anti-cancer and anti-obesity agents and describe their mechanisms to regulate cell metabolism. Written by global team of experts, Dietary Phytochemicals: A Source of Novel Bioactive Compounds for the Treatment of Obesity, Cancer and Diabetes describes the potentials of novel phytochemicals, their sources, and underlying mechanism of action. The chapters were drawn systematically and incorporated sequentially to facilitate proper understanding. This book is intended for nutritionists, physicians, medicinal chemists, drug developers in research and development, postgraduate students and scientists in area of nutrition and life sciences.

Nutrition plays a crucial role in supporting patients receiving treatment for cancer. Carefully considered nutritional options can help to manage patients with weight loss and cachexia, support the patient's ability to recover from surgery and cope with treatments such as chemotherapy and radiotherapy. Patients living with and beyond cancer can also benefit from advice on optimal nutrition and lifestyle changes.

Edited by Dr Clare Shaw, Consultant Dietitian at The Royal Marsden NHS Foundation Trust, "Nutrition and Cancer" takes an unrivalled look at this prevalent disease, offering the reader: An insight into the nutritional challenges faced for patients with cancerA practical guide to nutrition and dietetic practice in cancer careA detailed look at nutritional options for different diagnostic groupsContributions from a wide range of cancer specialists

An excellent resource for dietitians, clinical nutritionists, doctors, nurses and other health professionals working with cancer patients, this book is also a fascinating reference for students and researchers with an interest in the area.

This book presents unique compendium of groundbreaking ideas where scientists from many different backgrounds are united in their interest in interdisciplinary approaches towards origins and development of cancers, innovative ways of searching for cancer treatment and the role of cancer in the evolution. Chapters give an unequivocal slice of all areas that relate to a quest for understanding cancer and its origin as many-fold nonlinear system, complexity of the cancer developments, a search for cancer treatment using artificial intelligence and evolutionary optimisation, novel modelling techniques, molecular origin of cancer, the role of cancer in evolution of species, interpretation of cancer in terms of artificial life and artificial immune systems, swarm intelligence, cellular automata, computational systems biology, genetic networks, cellular computing, validation through in vitro/vivo tumour models and tumour on chip devices. The book is an inspiring blend of theoretical and experimental results, concepts and paradigms. Distinctive features The book advances widely popular topics of cancer origin, treatment and understanding of its progress The book is comprised of unique chapters written by world top experts in theoretical and applied oncology, complexity theory, mathematics, computer science. The book illustrates attractive examples of mathematical and computer models and experimental setups.

The book will discuss the molecular mechanisms of cancer diseases, stem cell proliferation and transformation into cancer cells beyond the physiological processes that occur in normal stem cell biology. Some of the key oncogenic events in cancer and their signaling pathways that regulate cell division cycle progression will be described considering prospects for using such knowledge in advanced cancer therapy. Each chapter shall provide an invaluable resource for information on the most current advances in the field, with discussion of controversial issues and areas of emerging importance

This year notes two major changes in the annual Detroit Cancer Symposium. The first is our intention of selecting top ics of broad interest to the cancer community and examining the subject from both a basic laboratory and clinical viewpoint. In this way, the importance of both elements of cancer research are noted and the interplay between them emphasized. Further, we believe that Symposia such as this act to stimulate the basic scientist and clinician to continue their studies with the know ledge of the impact that each has upon the other and the nec essary cooperation required to solve the cancer problem. The second change is the publication of this Symposium. The pre vious sixteen were not committed to manuscript form. Given the change in format and intent of the series, we believe that this and subsequent volumes will make important contributions to the cancer literature. The topic of "Biology and Therapy of Acute Leukemia" was chosen for the first Symposium because of its historical signif icance in cancer chemotherapy. The therapeutic rationale for human leukemia is the result of understanding the basic tumor biology largely derived from transplantable leukemias in exper imental animals. It is through these models, as discussed by Dr. Fred Valeriote, that we learned the cellular kinetics of leukemia, the antileukemic effects of new agents and the ef fect of growth perturbation by various chemotherapeutic agents and their combinations."

Transforming Growth Factor- ss in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ss (TGF- ss) in cancer treatment and therapy. The first volume, Basic and Clinical Biology, is divided into three parts. This volume's companion, Cancer Treatment in Therapy, examines transforming growth factor- ss in other developing and advanced cancers and methods of treatment and therapy.